DG
BBIO icon

DMC Group’s BridgeBio Pharma BBIO Stock Holding History

DMC Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
3,000
-500
-14% -$35K 0.15% 125
2026
Q1 		$260K Hold
3,500
– – 0.18% 126
2025
Q4 		$268K Buy
+3,500
New +$230K 0.18% 126

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

DMC Group's BBIO Position: Q2 2026 in Review

DMC Group reduced its BridgeBio Pharma (BBIO) stake by 14% in Q2 2026, selling an estimated $35K and leaving 3,000 shares worth $223K. The position accounts for 0.15% of the portfolio, ranked #125.

DMC Group first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $268K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • DMC Group held 3,000 shares of BridgeBio Pharma worth $223K as of Q2 2026.
  • DMC Group sold 500 BridgeBio Pharma shares in Q2 2026, an estimated $35K.
  • BridgeBio Pharma made up 0.15% of DMC Group's portfolio in Q2 2026, its #125 holding.
  • DMC Group first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • DMC Group's BridgeBio Pharma position peaked at $268K in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on DMC Group's 13F filing for Q2 2026, filed 28 Jul 2026.